We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-8.83%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$3.57B
AUM Growth
-$614M
Cap. Flow
+$51.4M
Cap. Flow %
1.44%
Top 10 Hldgs %
48.82%
Holding
78
New
14
Increased
15
Reduced
33
Closed
9
Avg Time Held
1.3 years
Top 10 Avg Time Held
1.1 years
Top 20 Avg Time Held
0.9 years

Top Buys

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$73M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$72.6M
3
ONEM
1Life Healthcare
ONEM
+$68.5M
4
MRK icon
Merck
MRK
+$64.9M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$53.9M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$116M
2
FTSV
Forty Seven, Inc. Common Stock
FTSV
+$109M
3
BSX icon
Boston Scientific
BSX
+$73.8M
4
CNC icon
Centene
CNC
+$44.2M
5
HCA icon
HCA Healthcare
HCA
+$42.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.88%
2 Industrials 0.87%
3 Miscellaneous 0.25%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
AKRO icon
51
DELISTED
Akero Therapeutics
AKRO
$12.1M 0.34%
569,513
-594,489
-51% -$12.8M
2019 Q2
3 quarters
ADPT icon
52
Adaptive Biotechnologies
ADPT
$3.83B
$11.5M 0.32%
414,400
-11,300
-3% -$315K
2019 Q2
3 quarters
CABA icon
53
Cabaletta Bio
CABA
$239M
$10.4M 0.29%
1,425,896
-5,800
-0.4% -$79.5K
2019 Q4
1 quarter
BNTX icon
54
BioNTech
BNTX
$22B
$9.94M 0.28%
170,200
-3,300
-2% -$128K
2019 Q4
1 quarter
STXS icon
55
Stereotaxis
STXS
$101M
$9.37M 0.26%
3,103,327
-65,981
-2% -$273K
2019 Q3
2 quarters
BMY.RT icon
56
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$9.08M 0.25%
+2,389,000
New +$7.87M
2020 Q1
0 quarters
ITMR
57
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
$7.36M 0.21%
+625,000
New +$8.52M
2020 Q1
0 quarters
RVMD icon
58
Revolution Medicines
RVMD
$38.1B
$6.65M 0.19%
+303,371
New +$8.4M
2020 Q1
0 quarters
XERS icon
59
Xeris Biopharma Holdings
XERS
$1.88B
$5.77M 0.16%
2,957,441
-43,200
-1% -$186K
2018 Q2
7 quarters
CBAY icon
60
DELISTED
Cymabay Therapeutics
CBAY
$4.07M 0.11%
2,750,616
-62,949
-2% -$106K
2017 Q3
10 quarters
PROF icon
61
Profound Medical
PROF
$220M
$3.9M 0.11%
+400,000
New +$5.19M
2020 Q1
0 quarters
GOSS icon
62
Gossamer Bio
GOSS
$53.6M
$2.64M 0.07%
3,246
-8
-0.2% -$8.36K
2019 Q1
4 quarters
SYRS icon
63
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.26M 0.04%
21,229
– –
2016 Q2
15 quarters
CLVS
64
DELISTED
Clovis Oncology, Inc.
CLVS
$633K 0.02%
+99,485
New +$798K
2020 Q1
0 quarters
CBIO icon
65
Crescent Biopharma
CBIO
$440M
$578K 0.02%
2,535
-10,903
-81% -$4.17M
2017 Q2
11 quarters
VAPO
66
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$471K 0.01%
3,125
-116,817
-97% -$10.5M
2018 Q4
5 quarters
OVID icon
67
Ovid Therapeutics
OVID
$420M
$363K 0.01%
121,950
– –
2017 Q2
11 quarters
ELGX
68
DELISTED
Endologix Inc
ELGX
$54K ﹤0.01%
78,755
– –
2015 Q4
17 quarters
CSLT
69
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$7K ﹤0.01%
10,229
– –
2018 Q2
7 quarters
BMY icon
70
Bristol-Myers Squibb
BMY
$122B
– –
-1,800,800
Closed -$116M –
BSX icon
71
Boston Scientific
BSX
$64.3B
– –
-1,631,200
Closed -$73.8M –
ELV icon
72
Elevance Health
ELV
$92.9B
– –
-100,800
Closed -$30.4M –
GH icon
73
Guardant Health
GH
$21.3B
– –
-389,700
Closed -$30.5M –
HCA icon
74
HCA Healthcare
HCA
$99.3B
– –
-285,200
Closed -$42.2M –
PTCT icon
75
PTC Therapeutics
PTCT
$4.94B
– –
-859,526
Closed -$41.3M –
1 2
3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return
TIA
Tandem Investment Advisors Charleston, South Carolina $1.49B AUM 12.33% 1-Year Est. Return

Redmile Group's Q1 2020 Portfolio in Review

As of Q1 2020, Redmile Group held 78 positions worth $3.57B, down 15% from $4.18B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Redmile Group's Q1 2020 filing shows 14 new, 15 increased, 33 reduced and 9 closed positions. Its largest new stake was Beam Therapeutics: 3,359,258 shares worth $60.5M. The largest sale was Bristol-Myers Squibb, an estimated $116M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Industrials and Miscellaneous.

  • Redmile Group's largest Q1 2020 buy was Beam Therapeutics: 3,359,258 shares worth $60.5M.
  • Redmile Group added most to Momenta Pharmaceuticals, Inc. in Q1 2020, an estimated $53.9M increase.
  • Redmile Group's biggest Q1 2020 reduction was Centene, cutting an estimated $44.2M.
  • Redmile Group fully exited Bristol-Myers Squibb in Q1 2020, selling an estimated $116M.
  • Redmile Group's ten largest holdings make up 49% of its $3.57B portfolio in Q1 2020.
  • Redmile Group opened 14 new positions and closed 9 in Q1 2020.
  • Redmile Group's portfolio value fell 15% quarter-over-quarter to $3.57B.

Based on Redmile Group's 13F filing for Q1 2020, filed 15 May 2020.